(Q42023464)

15 October 2017

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study (English)

1 reference

15 October 2017

Daphne T Adelman

1

1 reference

15 October 2017

Andrea Burgess

series ordinal

2

1 reference

15 October 2017

Philippa R Davies

series ordinal

3

1 reference

15 October 2017

14 December 2012

1 reference

Medical Devices: Evidence and Research

15 October 2017

1 reference

15 October 2017

5

1 reference

15 October 2017

103-109

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

15 October 2017

start time

1 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

The role of somatostatin analogues in the treatment of neuroendocrine tumours

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Medical progress: Acromegaly

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Understanding and meeting the needs of those using growth hormone injection devices

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3534535

Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23293542

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/MDER.S37831

1 reference

15 October 2017

1 reference

15 October 2017

PubMed publication ID

23293542

1 reference